Eli Lilly and Company (LLY) Stock Price & Analysis
Eli Lilly and Company (LLY) closed at USD 1,306.69 on Thursday, October 22, 2026, up 2.83% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 1,270.75; the Oct 22, 2026 session ranged USD 1,275.1–1,321.21 on volume of 2,654,387 shares. Market capitalization is $1.17T, with a 52-week range of USD 806.02–1,321.21 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:57 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LLY.md
Key facts (LLY)
- Last four reported quarters (through Jun 30, 2026): revenue $79.7B, net income $26.7B (33.5% margin) (SEC filings).
- Valuation: P/E 43.6x (avg 71.1x at the last 3 fiscal year-ends).
- 7 of 80 tracked superinvestors hold LLY (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 0 new, 0 added, 6 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 5 Form 4 filings, $34.6M; 1 not under a Rule 10b5-1 plan ($15.8M); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.06 on a 1–5 scale) (31 analysts), mean target USD 1,331.55 (range 930–1,600).
- Total return with dividends: 1Y +60.1% vs S&P 500 +14.9%; 5Y +461.0% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 6.67, revenue estimate $22.6B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LLY)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B | $79.7B |
| Gross profit | $21.0B | $21.9B | $27.0B | $36.6B | $54.1B | — |
| Net income | $5.58B | $6.24B | $5.24B | $10.6B | $20.6B | $26.7B |
| EPS (diluted) | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 | — |
| Gross margin | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% | — |
| Net margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% | 33.5% |
| Revenue growth | +15.4% | +0.8% | +19.6% | +32.0% | +44.7% | — |
| Cash + short-term investments | $3.91B | $2.21B | $2.93B | $3.42B | — | — |
| Total debt | $16.9B | $16.2B | $25.2B | $33.6B | $42.5B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (LLY)
P/E 43.6x · P/S 14.6x · P/B 34.4x · Earnings yield 2.29% · Dividend yield (paid, TTM) 0.50% · Buyback yield (TTM) 0.53%
P/E at fiscal year-ends: Dec 2025 46.8x, Dec 2024 65.9x, Dec 2023 100.5x.
Superinvestors (SEC 13F-HR, Q2 2026) (LLY)
7 of 80 tracked investors hold LLY (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 6.89% | $800M | Reduced -27.1% | Q2 2026 |
| Jensen Investment Management | 4.47% | $184M | Reduced -33.4% | Q2 2026 | |
| Mairs & Power | Mairs & Power Funds | 3.54% | $386M | Reduced -1.3% | Q2 2026 |
| Torray Funds | 0.06% | $477K | Unchanged | Q2 2026 | |
| Dodge & Cox Funds | Dodge & Cox | 0.03% | $49.5M | Reduced -1.8% | Q2 2026 |
| David Katz | Matrix Asset Advisors | 0.03% | $352K | Reduced -1.9% | Q3 2026 |
| Bill Nygren | Oakmark Funds | <0.01% | $517K | Reduced -4.2% | Q2 2026 |
Insider sales (SEC Form 4, open-market, last ~7 months) (LLY)
4 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Jonsson Patrik | EVP & President, LLY Int'l | 6,500 | $7.6M | 10.6% | Yes (adopted February 17, 2026) | Too little history (no open-market trades in 2024 or 2025) |
| 2026-08-10 | Zakrowski Donald A | SVP, Finance, & CAO | 2,000 | $2.4M | 38% | Yes (adopted May 11, 2026) | Routine (sold in Aug & Nov each year 2023–2025) |
| 2026-08-07 | Hakim Anat | EVP, GC & Secretary | 5,000 | $6.0M | 9% | Yes (adopted February 10, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-06-10 | Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | 2,500 | $2.9M | 7.7% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-06 | Lilly Endowment Inc | 15,828 | $15.8M | 0% | No | Routine (sold in Jul & Sep each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (LLY)
Consensus Buy (mean 2.06 on a 1–5 scale), 31 analysts; mean target USD 1,331.55 (low 930, high 1,600).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Leerink Partners | Target raised | Outperform | $1309 → $1316 |
| 2026-10-12 | RBC Capital | Reiterated | Outperform | $1500 |
| 2026-10-08 | Cantor Fitzgerald | Target raised | Overweight | $1410 → $1440 |
| 2026-10-07 | Morgan Stanley | Target raised | Overweight | $1419 → $1430 |
| 2026-09-28 | JP Morgan | Target raised | Overweight | $1400 → $1500 |
| 2026-09-22 | TD Cowen | Reiterated | Buy | $1250 |
| 2026-09-18 | Guggenheim | Target raised | Buy | $1273 → $1284 |
| 2026-09-10 | HSBC | Target raised | Reduce | $850 → $940 |
| 2026-08-07 | Truist Securities | Target raised | Buy | $1370 → $1376 |
| 2026-08-06 | Wells Fargo | Target raised | Overweight | $1280 → $1330 |
| 2026-08-06 | Cantor Fitzgerald | Target raised | Overweight | $1350 → $1410 |
| 2026-07-15 | Citigroup | Target raised | Buy | $1500 → $1600 |
Total return (dividends reinvested) (LLY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +60.1% | +461.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +60.4% | +41.1% |
| Volatility (annualized) | 34.7% | 33.5% |
| Max drawdown | -23.2% (Nov 2025→Apr 2026) | -34.5% (Aug 2024→Aug 2025) |
LLY revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Net product revenue | $21.40B | 93.2% | +45.3% |
| Cardiometabolic Health | $18.35B | 79.9% | +61.8% |
| Mounjaro | $9.94B | 43.3% | +91.2% |
| Zepbound | $4.93B | 21.5% | +45.8% |
| Oncology | $2.57B | 11.2% | +6.5% |
| Collaboration and Other Revenue | $1.57B | 6.8% | +88.8% |
| Verzenio | $1.47B | 6.4% | -1.0% |
| Immunology | $1.42B | 6.2% | +12.8% |
| Jardiance | $1.23B | 5.4% | +78.6% |
| Trulicity | $1.22B | 5.3% | +11.6% |
| Other oncology | $1.10B | 4.8% | +18.6% |
| Other cardiometabolic health | $1.03B | 4.5% | +5.2% |
| Taltz | $856.0M | 3.7% | +0.9% |
| Other immunology | $561.0M | 2.4% | +37.5% |
| Neuroscience | $429.0M | 1.9% | +24.7% |
| Other | $205.0M | 0.9% | +1.5% |
| Total revenue | $22.97B | 100% | — |
LLY revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| U.S. | $14.41B | 62.7% | +33.3% |
| Outside U.S. | $8.56B | 37.3% | +80.5% |
| — Europe (part of Outside U.S.) | $4.12B | 17.9% | +59.9% |
| — Rest of world (part of Outside U.S.) | $2.88B | 12.5% | +143.4% |
| — China (part of Outside U.S.) | $941.0M | 4.1% | +101.9% |
| — Japan (part of Outside U.S.) | $628.0M | 2.7% | +20.5% |
| Total revenue | $22.97B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
LLY suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Almirall | “We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe.” |
| Partner | Chugai Pharmaceutical | “We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us with the worldwide development and commercialization rights to orforglipron.” |
Quoted from the company's 10-K filed Feb 12, 2026.
Companies that name LLY in their SEC reports
| Relationship to LLY | Company | Filing | Sentence |
|---|---|---|---|
| competitor | Incannex Healthcare Inc. (IXHL) | 10-K Sep 25, 2026 | “Competitors working on novel biopharmaceuticals focused on modulation of the serotonin and dopamine systems include AtaiBeckley Inc. (recently acquired by Eli Lilly and Company), Compass Pathways plc, GH Research plc and others.” |
| competitor | iBio, Inc. (IBIO) | 10-K Aug 28, 2026 | “Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, MedImmune, LLC (a wholly owned subsidiary of AstraZeneca PLC), Johnson & Johnson, Pfizer Inc., Merck KGaA and Sanofi SA, and more established biotechnology companies such as Genentech, Inc. (a member …” |
| competitor | BIOVIE INC. (BIVI) | 10-K Aug 13, 2026 | “Similarly, other companies, such as Biogen and Eli Lilly, are developing treatments for AD and PD, which could compete indirectly or directly” |
| partner | Evotec SE (EVO) | 20-F Apr 8, 2026 | “Based on the strength of our molecular CKD patient database, we have built four partnerships in kidney diseases in the last almost ten years with prominent pharmaceutical companies such as Bayer, Vifor (now "CSL Vifor"), Novo Nordisk, Eli Lilly, and Chinook (now a Novartis company).” |
| competitor | Inventiva S.A. (IVA) | 20-F Apr 8, 2026 | “Furthermore, we face strong competition for enrollment from competitors who have received marketing authorization, such as Madrigal with Rezdiffra, and Novo Nordisk with Wegovy, and others who are conducting ongoing clinical trials evaluating their drug candidates in MASH, such as Boehringer Ingelheim, 89Bio/Roche, Akero Therapeutics (a subsidiary of Novo Nordisk), Boston Pharmaceuticals, GSK, and Eli Lilly and Co…” |
| competitor | Greenland Mines Ltd (GRML) | 10-K Apr 1, 2026 | “and lecanumab (Lilly:Leqembi) were FDA approved and will potentially compete with Roche, Bristol-Myers/Celgene, and others developing” |
| partner | MANGOCEUTICALS, INC. (MGRX) | 10-K Apr 1, 2026 | “(marketed by Lilly ICOS LLC, a joint venture between Eli Lilly and Company and ICOS Corporation) and their generic forms.” |
| competitor | HCW Biologics Inc. (HCWB) | 10-K Mar 31, 2026 | “The oncology T‑cell engager landscape is highly competitive, with established and emerging programs from biotech and pharmaceutical companies, including AbbVie, BMS, Sanofi, Lilly, Amgen's bispecifics, Genmab/Daiichi Sankyo's multispecific platforms, and numerous CD3‑engager programs in development targeting both hematologic and solid tumors.” |
| competitor | Alaunos Therapeutics, Inc. (TCRT) | 10-K Mar 31, 2026 | “Key competitors in the obesity space include (but are not limited to) companies such as Novo Nordisk, Eli Lilly, Amgen, Pfizer, Viking Therapeutics, Structure Therapeutics, and others.” |
| partner | MeiraGTx Holdings plc (MGTX) | 10-K Mar 30, 2026 | “On November 7, 2025 (the "Effective Date"), our affiliates MeiraGTx Ocular UK Limited ("MeiraGTx Ocular"), MeiraGTx Limited and MeiraGTx UK II Limited, entered into a strategic collaboration and license agreement with Eli Lilly and Company ("Lilly") (the "Lilly Collaboration Agreement") for the research, development and commercialization of genetic medicines in and related to the area of ophthalmology.” |
| competitor | Bicara Therapeutics Inc. (BCAX) | 10-K Mar 30, 2026 | “We expect to compete with currently commercially available therapies for the treatment of HNSCC, including pembrolizumab (marketed as Keytruda by Merck & Co); the combination of pembrolizumab, platinum chemotherapy and 5-fluorouracil; and the combination of cetuximab (marketed as Erbitux by Eli Lilly & Company in the U.S. and by Merck KGaA outside of the U.S.), platinum chemotherapy and 5-fluorouracil.” |
| partner | Aktis Oncology, Inc. (AKTS) | 10-K Mar 30, 2026 | “We also have a discovery collaboration with Eli Lilly and Company, or Eli Lilly, to generate novel anticancer radiopharmaceuticals against targets beyond the scope of our unpartnered pipeline programs.” |
| competitor | Curanex Pharmaceuticals Inc (CURX) | 10-K Mar 30, 2026 | “of our competitors have far greater marketing and research capabilities than us, such as Regeneron/Sanofi, Pfizer, LEO Pharma, Eli Lilly,” |
| competitor | Cytosorbents Corp (CTSO) | 10-K Mar 30, 2026 | “Given current U.S. and Canadian prescribing trends that favor Brilinta over its competitors, Plavix (clopidogrel, BMS, Sanofi) and Effient (prasugrel, Daiichi Sankyo, Eli Lilly), and the recent availability of generic ticagrelor in the U.S. since mid-2025, the number of eligible patients could increase substantially.” |
| supplier | OXFORD INDUSTRIES INC (OXM) | 10-K Mar 27, 2026 | “Lilly Pulitzer's net sales to its 10 largest wholesale customers represented approximately 10% of Lilly Pulitzer's net sales in Fiscal 2025 with its largest customer representing less than 5% of Lilly Pulitzer's net sales.” |
LLY company outlook (results filed Aug 5, 2026)
- “The following table summarizes the company's updated full-year 2026 non-GAAP financial guidance, reflecting the continued strong revenue performance in Q2.”
- “(3) Guidance does not include acquired in-process research and development (IPR&D) incurred after June 30, 2026.”
- “(4) Assumes shares outstanding of approximately 894 million and foreign currency exchange rate assumptions of 1.14 (Euro), 153 (Yen) and 7.1 (Yuan) 6 Webcast of Conference”
Quoted word-for-word from the SEC 8-K results press release.
LLY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $6.67 | $9.44 | -29.4% | $22.62B | 18 |
| Next quarter (ends Dec 2026) | $10.17 | $9.95 | +2.2% | $23.60B | 16 |
| Current fiscal year (ends Dec 2026) | $34.59 | $34.63 | -0.1% | $88.68B | 27 |
| Next fiscal year (ends Dec 2027) | $47.22 | $44.87 | +5.2% | $102.11B | 25 |
LLY options: expected move
Options price a move of about ±6.8% (±$89.65) by Oct 30, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±7.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 57.8% | ±6.8% |
| Nov 6, 2026 | 14 | 49.0% | ±7.9% |
| Nov 13, 2026 | 21 | 43.3% | ±8.5% |
| Nov 20, 2026 | 28 | 40.1% | ±9.0% |
| Nov 27, 2026 | 35 | 38.1% | ±9.5% |
| Dec 4, 2026 | 42 | 37.2% | ±10.2% |
| Dec 18, 2026 | 56 | 37.1% | ±11.6% |
| Jan 15, 2027 | 84 | 35.0% | ±13.5% |
30-day implied volatility 40.1% vs 25.9% realized over the last 30 trading days. Put/call ratio (volume) 0.79. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:57 UTC)
| Price | USD 1,306.69 |
|---|---|
| Change | ▲ 2.83% (up) |
| Previous Close | USD 1,270.75 |
| Open | USD 1,281.76 |
| Day Range | USD 1,275.1 – 1,321.21 |
| 52-Week Range | USD 806.02 – 1,321.21 |
| Volume | 2,654,387 shares |
| Market Cap | $1.17T |
| Exchange | NYQ |
Technical Analysis (LLY)
Nexqual's technical model rates LLY "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:57 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 72.06 (overbought) |
| vs SMA50 | Above (USD 1,185.32) |
| MACD | 30.14 (positive) |
Analyst Ratings (LLY)
Wall Street analysts rate LLY "Buy" based on 31 analysts, with a mean price target of USD 1,331.55 (range USD 930–1,600), per Nexqual as of October 23, 2026 at 09:57 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 31 |
| Mean Target | USD 1,331.55 |
| High Target | USD 1,600 |
| Low Target | USD 930 |
| Buy / Hold / Sell | 26 / 3 / 2 |
Earnings (LLY)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 6.67 |
| Revenue Estimate | $22.62B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 8.38 vs est 6.58 ▲ beat |
| 2026-03-31 | USD 8.55 vs est 6.79 ▲ beat |
| 2025-12-31 | USD 7.54 vs est 6.91 ▲ beat |
| 2025-09-30 | USD 7.02 vs est 5.89 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:57 UTC.
Financials & Fundamentals (LLY)
| Total Revenue | $79.67B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +47.70% |
| Gross Margin | +83.40% |
| Operating Margin | +54.22% |
| Profit Margin | +33.53% |
| ROE | +102.29% |
| Debt / Equity | 1.62 |
| Current Ratio | 1.36 |
| Total Cash | $8.95B |
| Total Debt | $54.91B |
Source: Nexqual, October 23, 2026 at 09:57 UTC.
Financial Health Score (LLY)
Nexqual rates Eli Lilly and Company's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:57 UTC.
| Growth | Strong — Revenue +45% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 83%, operating 54% (last 12 months) |
| Balance Sheet | Weak — $9.91B cash and investments vs $42.5B debt (Sep 2025, SEC) |
| Cash Flow | Solid — Operating cash flow $16.8B (FY ended Dec 2025, 10-K) |
| Efficiency | Strong — ROE 102%, ROA 20.4% |
Ownership (LLY)
| Insider Ownership | +0.16% |
|---|---|
| Institutional Ownership | +85.36% |
| Shares Outstanding | 891.74M |
| Float | 888.94M |
| Short % of Float | +0.79% |
Source: Nexqual, October 23, 2026 at 09:57 UTC.
Leadership (LLY)
Eli Lilly and Company is led by David A. Ricks, Chairman, President & CEO, per Nexqual as of October 23, 2026 at 09:57 UTC.
| Chairman, President & CEO | David A. Ricks |
|---|---|
| Executive VP & CFO | Lucas E. Montarce |
| Chief Scientific & Product Officer and President of Lilly Research Laboratories | Daniel M. Skovronsky |
| Executive VP, President of Lilly Oncology & Head of Corporate Business Development | Jacob S. Van Naarden |
| Senior Vice President of Investor Relations | Michael Czapar |
Major Backers & Investors (LLY)
Notable institutional backers of Eli Lilly and Company include Lilly Endowment, Inc, PNC Financial Services Group, Inc., FMR, LLC, according to Nexqual as of October 23, 2026 at 09:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lilly Endowment, Inc | 9.57% |
| PNC Financial Services Group, Inc. | 5.45% |
| FMR, LLC | 3.02% |
| Capital Group | 2.22% |
| Morgan Stanley | 1.72% |
| Fidelity | 1.09% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.91% |
| BlackRock | 7.17% |
| State Street | 3.85% |
| Geode Capital | 2.16% |
Source: Nexqual, October 23, 2026 at 09:57 UTC.
From Eli Lilly and Company's Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Currently, these government prices generally apply beginning at nine years (for medicines approved under a New Drug Application) or thirteen years (for medicines approved under a Biologics License Application) following FDA approval or licensure for the molecule and are set at a price that generally represents a significant discount from existing list prices to wholesalers and direct purchasers.
Partnerships
- In August 2023, HHS selected Jardiance, which is part of our collaboration with Boehringer Ingelheim, as one of the first ten medicines subject to government-set prices effective in 2026.
- To supplement our internal efforts, we collaborate with others, including academic institutions and research-based pharmaceutical and biotechnology companies.
Legal & Regulatory Risks (Item 1A, quoted)
- We are party to litigation and investigations, which could adversely affect our business.
- We are subject to evolving and complex tax laws, which may result in additional liabilities.
- Regulatory compliance problems could be damaging to the company.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JNJ | Johnson & Johnson | USD 267.61 | ▲ 3.81% |
| ABBV | AbbVie Inc. | USD 285.19 | ▲ 0.14% |
| MRK | Merck & Company, Inc. | USD 147.24 | ▼ 1.76% |
| NVS | Novartis AG | USD 156.27 | ▲ 1.52% |
| AZN | AstraZeneca PLC | USD 172.57 | ▲ 2.45% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:57 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt